PMN:TSX; ARFXF:OTCQB

ProMIS Neurosciences Inc.

ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic misfolded proteins implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary computational modeling techniques. The Company applies its molecular dynamics, computational discovery platform -ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts.
PMN:TSX ARFXF:OTCQB

Expert Comments:

headshot of Douglas Loe

Douglas Loe, Leede Jones Gable

(5/11/22)
"We are initiating coverage on Massachusetts-based, central nervous system-focused, antibody-based drug developer ProMIS Neurosciences Inc. with a Speculative Buy rating. . .the company's core competency lies in its expertise in generating monoclonal antibodies that target conformational epitopes that are expressed either predominantly or exclusively on misfolded or aggregated proteins that in being misfolded/aggregated contribute to disease."

read more >

Steve Silver, Argus Research

(4/13/22)
"We view ProMIS Neurosciences Inc.'s path to clinical value inflection favorably, given that its Phase 1b study will be open label and biomarker checked on a monthly basis, which should provide evidence of effect at a relatively early stage. In addition, we expect the appetite for mergers and acquisitions and financing for diseases such as Alzheimer's to improve over 2022, as new late-stage data is reported."

read more >

Experts Following This Company

headshot of Douglas Loe
Douglas Loe, Managing Director & Analyst, Healthcare and Biotechnology – Leede Jones Gable
Steve Silver, Outside IR – KCSA Strategic Communications
John Vandermosten, CFA – Zacks Small-Cap Research

Company News 

5/17/2022 – ProMIS Neurosciences presents at the 2022 Neuro4D International Conference

5/13/2022 – CORRECTION: ProMIS Neurosciences Announces First Quarter 2022 Results

5/13/2022 – ProMIS Holds Annual and Special Meeting of Shareholders All Resolutions Approved

5/3/2022 – Independent Proxy Advisory Firms, ISS and Glass Lewis, Recommend ProMIS Shareholders Vote FOR All Proposed Items at the Upcoming Annual and Special Meeting of Shareholders

4/28/2022 – ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)

4/19/2022 – ProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical Officer

4/7/2022 – ProMIS Neurosciences Presents at the 2022 American Academy of Neurology Annual Meeting

4/7/2022 – ProMIS Files Management Information Circular in Connection with Annual General and Special Meeting of Shareholders

3/24/2022 – ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit

3/22/2022 – ProMIS Neurosciences Presents Preclinical Results of its Experimental Alzheimer's Vaccine at the 2022 International AD/PDTM Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

3/17/2022 – ProMIS Neurosciences Announces Fiscal Year 2021 Results

3/10/2022 – ProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PDTM) and Related Neurological Disorders

3/2/2022 – ProMIS Neurosciences' PMN310 antibody demonstrates significant cognitive benefit in a mouse model of Alzheimer's disease

The information provided above is from analysts, newsletters, the company and other contributors.

ProMIS Neurosciences Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
 
Alzheimer’s antibody therapy potentially “Best” of next generation
 
Highly selective antibody technology targets only misfolded (toxic) proteins
 
Proprietary discovery platform supports broad, rapidly expanding portfolio
catalyst Calendar
Q2
2022
Start IND enabling studies for Parkinson’s and ALS lead candidates: H2 2022
Q4
2022
PMN310 for Alzheimer’s: IND preparation complete Q4’2022
Q1
2023
First clinical trial Q12023